ABSTRACT
Introduction Two drugs are often included as part of the antiplatelet armamentarium: dipyridamole and cilostazol. Dipyridamole has been available clinically for about the last 40 years and played an important role as adjunctive therapy in the early days of surgical and percutaneous intervention. Cilostazol is a more recent addition to our pharmacologic options, has an established role in the management of peripheral arterial disease, and has gained a more recent attention with favorable new data in reducing restenosis following coronary stenting.
